ReviewHealth science reports2022
The role of NK and NKT cells in the pathogenesis and improvement of multiple sclerosis following disease-modifying therapies.
Review in Health science reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 15 citations in OpenAlex.
- Feasibility and Diagnostic Utility of Mucosal T-Cell Flow Cytometry for Intestinal Graft-Versus-Host Disease.Gastro hep advances · 2026Article
- Immune-gut-metabolite Interactions in Multiple Sclerosis: A Mendelian Randomization and Mediation Study.Current neurovascular research · 2026Article
- High metabolic activity in positron emission tomography and systemic inflammation occurring years after exposure cessation in engineered stone silicosis.Scientific reports · 2025Article
- Natural killer cells in multiple sclerosis: foe or friends?Frontiers in cellular neuroscience · 2025Review
- High-Fat Diet Exacerbates Neuroinflammation and Disease Severity in a Rat Model of Multiple Sclerosis.International journal of preventive medicine · 2025Article
- Longitudinal analysis of peripheral immune cells in patients with multiple sclerosis treated with anti-CD20 therapy.Annals of clinical and translational neurology · 2024Article
- NK Cell Levels Correlate with Disease Activity in Patients with Multiple Sclerosis on Ocrelizumab/Rituximab Therapy.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Role of innate T cells in necrotizing enterocolitis.Frontiers in immunology · 2024Review
- People with Primary Progressive Multiple Sclerosis Have a Lower Number of Central Memory T Cells and HLA-DRCells · 2023Article
- Arginine vasopressin hormone receptor antagonists in experimental autoimmune encephalomyelitis rodent models: A new approach for human multiple sclerosis treatment.Frontiers in neuroscience · 2023Review
- The role of NK and NKT cells in the pathogenesis and improvement of multiple sclerosis following disease-modifying therapies.Health science reports · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMultiple sclerosis (MS) is an autoimmune inflammatory disease of the central nervous system (CNS) that T cells become autoreactive by recognizing CNS antigens. Both innate and adaptive immune systems are involved in the pathogenesis of MS. In recent years, the impact of innate immune cells on MS pathogenesis has received more attention. CD56
aimWe aimed to evaluate the influence of MS therapeutic agents on NK and NKT cells and NK cell subtypes. MATERIALS AND
methodsThe possible mechanism of each MS therapeutic agent has been presented here, focusing on the effects of different disease-modifying therapies on the number of NK and NKT subtypes.
resultsExpansion of CD56
conclusionExpansion of CD56
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.